NasdaqGM - Nasdaq Real Time Price USD

Alimera Sciences, Inc. (ALIM)

3.6300

+0.0400

(+1.11%)

At close: April 24 at 4:00 PM EDT

Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ATLANTA, March 20, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced that, pursuant to Nasdaq Listing Rule 5635(c)(4) and in connection with the appointments of (i) Mr. Todd Wood as President of U.S. Operations of the Company, (ii) Mr. Elliot Maltz as Chief Financial

GlobeNewswire last month

ALIM
+1.11%
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network

Protocol AL is studying ILUVIEN or faricimab (6.0 mg) injections versus observation for the prevention of visual acuity loss due to radiation retinopathy ATLANTA, March 19, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that the first patient has been randomized in the DRCR Retina Network’

GlobeNewswire last month

ALIM
+1.11%
Alimera Sciences, Inc. (NASDAQ:ALIM) Q4 2023 Earnings Call Transcript

Alimera Sciences, Inc. (NASDAQ:ALIM) Q4 2023 Earnings Call Transcript March 7, 2024 Alimera Sciences, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Sciences Fourth […]

Insider Monkey last month

ALIM
+1.11%
Q4 2023 Alimera Sciences Inc Earnings Call

Q4 2023 Alimera Sciences Inc Earnings Call

Thomson Reuters StreetEvents last month

ALIM
+1.11%
Alimera Sciences Inc (ALIM) Reports Significant Revenue Growth in Q4 and Full Year 2023

Company Increases 2024 Revenue Guidance Amidst Strong Performance

GuruFocus.com last month

ALIM
+1.11%
Alimera Sciences (ALIM) Reports Q4 Loss, Tops Revenue Estimates

Alimera Sciences (ALIM) delivered earnings and revenue surprises of -450% and 4.81%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks last month

ALIM
+1.11%
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results

Q4 Net Revenues up 88% to $26.3 million vs. Q4 20222023 Net Revenues up 49% to $80.8 million vs. 2022Increases 2024 Revenue Guidance ATLANTA, March 07, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the fourth quarter and full year 2023. Alimera will host a confer

GlobeNewswire last month

ALIM
+1.11%
Alimera Sciences, Inc. (NASDAQ:ALIM) Has Found A Path To Profitability

With the business potentially at an important milestone, we thought we'd take a closer look at Alimera Sciences, Inc.'s...

Simply Wall St. last month

ALIM
+1.11%
Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update

Conference Call to be held the same day at 9:00am Eastern TimeATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report fourth quarter and full year 2023 financial results on March 7, 2024, prior to the market open. Management will host a conference call at 9

GlobeNewswire last month

ALIM
+1.11%
The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®

NICE Final Draft Guidance recommends providing National Health System (NHS) patients with a phakic lens access to the only sustained-release treatment lasting up to 36 months for chronic diabetic macular edema (DME)ATLANTA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that the N

GlobeNewswire 2 months ago

ALIM
+1.11%
Alimera Sciences (NASDAQ:ALIM) shareholders have endured a 69% loss from investing in the stock five years ago

While it may not be enough for some shareholders, we think it is good to see the Alimera Sciences, Inc. ( NASDAQ:ALIM...

Simply Wall St. 2 months ago

ALIM
+1.11%
Alimera Completes Recruitment for the Synchronicity Study

Study with YUTIQ® has Surpassed Goal of 100 Patients EnrolledATLANTA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces that it has completed enrollment for the company’s Synchronicity Study, a prospective, open-label clinical study evaluating the safety and efficacy of YUTIQ (

GlobeNewswire 3 months ago

ALIM
+1.11%
Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Alimera Sciences Names Elliot Maltz as Chief Financial Officer Elliot Maltz, CFO of Alimera Sciences ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced that Elliot Maltz, C.P.A., has been named Chief Financial Officer effective immediately. “Elliot jo

GlobeNewswire 3 months ago

ALIM
+1.11%
Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Tood Wood Headshot Todd Wood, President, U.S. Operations, Alimera Sciences ATLANTA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced the appointment of Todd Wood as President U.S. effective immediately. “As we prepare to enter 2024 with a significantly large

GlobeNewswire 4 months ago

ALIM
+1.11%
Alimera Appoints Maggie A. Pax to Its Board of Directors

Maggie A. Pax Maggie A. Pax Appointed to Board of Directors of Alimera Sciences ATLANTA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of Maggie A. Pax to its Board of Directors. Ms. Pax presently serves on the board of several life sciences companies. “Maggie’

GlobeNewswire 5 months ago

ALIM
+1.11%
Alimera Announces Scientific Data Highlighting ILUVIEN® To Be Presented at the American Academy of Ophthalmology

ATLANTA, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that clinical data for ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg taken from the three-year, phase IV, real-world observational PALADIN study evaluating the long-term safety of ILUVIEN for patients with di

GlobeNewswire 5 months ago

ALIM
+1.11%
Alimera Sciences, Inc. (NASDAQ:ALIM) Q3 2023 Earnings Call Transcript

Alimera Sciences, Inc. (NASDAQ:ALIM) Q3 2023 Earnings Call Transcript October 26, 2023 Alimera Sciences, Inc. beats earnings expectations. Reported EPS is $-0.06, expectations were $-0.41. Operator: Ladies and gentlemen, thank you for standing by. Good morning, and welcome to the Alimera Sciences Third Quarter 2022 [2023] (sic) Financial Results and Corporate Update Conference Call. [Operator […]

Insider Monkey 5 months ago

ALIM
+1.11%
Alimera Sciences Inc (ALIM) Reports Q3 2023 Financial Results

Record net revenue and significant decrease in net loss highlight the quarter

GuruFocus.com 5 months ago

ALIM
+1.11%
Alimera Sciences (ALIM) Reports Q3 Loss, Misses Revenue Estimates

Alimera Sciences (ALIM) delivered earnings and revenue surprises of 85.37% and 4.25%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks 5 months ago

ALIM
+1.11%
Alimera Sciences Reports Third Quarter 2023 Results

Net Revenue up 72% to $23.4 Million vs. Q3 2022Net Loss Decreased by 74% to $1.4 Million vs. Q3 2022Adjusted EBITDA of $5.4 Million in Q3 2023Successful Integration of YUTIQ into the U.S. Segment ATLANTA, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced financial results for

GlobeNewswire 5 months ago

ALIM
+1.11%

Performance Overview

Return	ALIM	S&P 500
YTD	-15.97%	+6.33%
1-Year	+75.36%	+22.70%
3-Year	-66.07%	+21.33%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Alimera Sciences, Inc. (ALIM)

Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network

Alimera Sciences, Inc. (NASDAQ:ALIM) Q4 2023 Earnings Call Transcript

Q4 2023 Alimera Sciences Inc Earnings Call

Alimera Sciences Inc (ALIM) Reports Significant Revenue Growth in Q4 and Full Year 2023

Alimera Sciences (ALIM) Reports Q4 Loss, Tops Revenue Estimates

Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results

Alimera Sciences, Inc. (NASDAQ:ALIM) Has Found A Path To Profitability

Alimera Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024, and Provide Corporate Update

The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®

Alimera Sciences (NASDAQ:ALIM) shareholders have endured a 69% loss from investing in the stock five years ago

Alimera Completes Recruitment for the Synchronicity Study

Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Alimera Appoints Maggie A. Pax to Its Board of Directors

Alimera Announces Scientific Data Highlighting ILUVIEN® To Be Presented at the American Academy of Ophthalmology

Alimera Sciences, Inc. (NASDAQ:ALIM) Q3 2023 Earnings Call Transcript

Alimera Sciences Inc (ALIM) Reports Q3 2023 Financial Results

Alimera Sciences (ALIM) Reports Q3 Loss, Misses Revenue Estimates

Alimera Sciences Reports Third Quarter 2023 Results

Performance Overview